Download PDF
Semin Thromb Hemost 2000; 26(5): 503-512
DOI: 10.1055/s-2000-13206
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Endothelial Dysfunction in Diabetes Mellitus

Stephan Schiekofer, Bernd Balletshofer, Martin Andrassy, Angelika Bierhaus, Peter P. Nawroth
  • Section of Vascular Medicine, Department of Medicine IV, University of Tübingen, Tübingen, Germany
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Diabetes mellitus and impaired glucose tolerance are linked to increased cardiovascular morbidity and mortality. Vascular disease is directly associated with plasma glucose levels, and reduction of these levels forestalls to a certain extent the vascular complications of diabetes, such as myocardial infarction, nephropathies, and retinopathies. In addition to hyperglycemia, there are other risk factors that play a prominent role, such as hypertension, hyperlipidemia, and genetic factors. Endothelial dysfunction is one of the major factors in the development of cardiovascular disease. The vascular endothelium regulates the blood flow by tightly controlling the coagulation system, cell-cell interaction, and vascular tone. These functions are disturbed in diabetic patients. In diabetics, endothelin-1 levels are increased, leading to vasoconstriction. Endothelin levels are directly related to plasma glucose levels. In addition, the endothelial cell-NO axis is disturbed. NO release and function are impaired. This seems to be dependent upon hyperglycemia and genetic factors. Impaired NO function also results in vasoconstriction. Furthermore, enhanced vascular permeability is seen in diabetics. This appears to be related to impaired endothelial cell relaxation and reactive oxygen species as well as advanced glycosylated end products (AGEs). The complex changes seen in diabetes and even prediabetes are therefore related to numerous derailments related to endothelial dysfunction, and no single therapeutic approach is likely to solve the problem of vascular complications.

KEYWORD

Diabetes - endothelium - hyperglycemia - vascular permeability - cardiovascular disease

REFERENCES

  • 1 Eriksson K F, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö preventive trial with diet and exercise.  Diabetologia . 1998;  41 1010-1016
    CrossrefPubMedGoogle Scholar
  • 2 Uusitupa M, Siitonen O, Aro A, Pyörälä K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects.  Diabetologia . 1985;  28 22-27
    CrossrefPubMedGoogle Scholar
  • 3 Eriksson J, Lindström J, Valle T. Prevention of type II diabetes in subjects with impaired glucose tolerance: The diabetes prevention study (DPS) in Finland.  Diabetologia . 1999;  40 793-801
    PubMedGoogle Scholar
  • 4 Tominaga M, Eguchi H, Manaka H. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose.  Diabetes Care . 1999;  22 920-924
    CrossrefPubMedGoogle Scholar
  • 5 Kurtschiev T, Koehler C, Schaper F. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals.  Diabetologia . 1998;  41 706-712
    CrossrefPubMedGoogle Scholar
  • 6 Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes.  Diabetes . 1999;  48 937-942
    CrossrefPubMedGoogle Scholar
  • 7 Valensi P, Giroux C, Ghalayini B, Attali J R. Diabetic peripheral neuropathy: Effects of age duration of diabetes, glycemic control, and vascular factors.  J Diabetes Complications . 1997;  11 27-34
    CrossrefPubMedGoogle Scholar
  • 8 Schmidt M I, Duncan B B, Sharrett A R. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): A cohort study.  Lancet . 1999;  353 1649-1652
    CrossrefPubMedGoogle Scholar
  • 9 Wu J T. Review of diabetes: Identification of markers for early detection, glycemic control, and monitoring clinical complications.  J Clin Lab Anal . 1993;  7 293-300
    PubMedGoogle Scholar
  • 10 Winkler G, Lakatos P, Salamon F. Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients.  Diabetic Med . 1999;  16 207-211
    CrossrefPubMedGoogle Scholar
  • 11 Koch M, Rett K, Volk A. The tumor necrosis factor alpha- 238 G → A and -308 G → A promoter polymorphisms are not associated with insulin sensitivity and insulin secretion in young healthy relatives of type II diabetic patients.  Diabetologia . 2000;  43 181-184
    CrossrefPubMedGoogle Scholar
  • 12 UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet . 1998;  352 837-853
    CrossrefPubMedGoogle Scholar
  • 13 DCCT: Diabetes Control and Complications Trial. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial.  Diabetes . 1996;  45 1289-1298
    CrossrefPubMedGoogle Scholar
  • 14 Gu K, Cowie C, Harris M. Diabetes and decline in heart disease mortality in US adults.  JAMA . 1999;  281 1291-1297
    CrossrefPubMedGoogle Scholar
  • 15 Vaccarino V, Parsons L, Every N R, Barron H V, Krumholz H M. Sex-based differences in early mortality after myocardial infarction.  N Engl J Med . 1999;  341 217-225
    CrossrefPubMedGoogle Scholar
  • 16 Haffner S M, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med . 1998;  339 229-234
    CrossrefPubMedGoogle Scholar
  • 17 Gaede P, Vedel P, Parving H H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study.  Lancet . 1999;  353 617-622
    CrossrefPubMedGoogle Scholar
  • 18 Baron A D. Vascular reactivity.  Am J Cardiol . 1999;  84 25-27
    PubMedGoogle Scholar
  • 19 Simon B C, Noll B, Maisch B. Endothelial dysfunction: Update and clinical implications.  Herz . 1999;  24 62-71
    PubMedGoogle Scholar
  • 20 Stern D M, Esposito C, Gerlach H. Endothelium and regulation of coagulation.  Diabetes Care . 1991;  14 160-166
    PubMedGoogle Scholar
  • 21 Rao K, Chouhan V, Chen X, Sun L, Boden G. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men.  Diabetes . 1999;  48 1156-1161
    PubMedGoogle Scholar
  • 22 Fenner E, King G L. Vascular dysfunction in diabetes mellitus.  Lancet . 1997;  350(Suppl I) 9-13
    CrossrefPubMedGoogle Scholar
  • 23 Neri S, Bruno C M, Leotta C. Early endothelial alterations in non-insulin-dependent diabetes mellitus.  Int J Clin Lab Res . 1998;  28 100-103
    CrossrefPubMedGoogle Scholar
  • 24 Stehouwer C DA, Lambert J, Donker A JM, van Hinsbergh W M V. Endothelial dysfunction and pathogenesis of diabetic angiopathy.  Cardiovasc Res . 1997;  34 55-68
    CrossrefPubMedGoogle Scholar
  • 25 Vehkavaara S, Seppala-Lindroos A, Westerbacka J. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose.  Diabetes Care . 1999;  22 2055-2060
    PubMedGoogle Scholar
  • 26 Miyauchi T, Tomobe Y, Shiba R. Involvement of endothelin in the regulation of human vascular tonus. Potent vasoconstrictor effect and existence in endothelial cells.  Circulation . 1990;  81 1874-1880
    PubMedGoogle Scholar
  • 27 Lerman A, Edwards B S, Hallett J W. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis.  N Engl J Med . 1991;  325 997-1001
    PubMedGoogle Scholar
  • 28 Quehenberger P, Bierhaus A, Fasching P. Endothelin-1 transcription is under control of nuclear factor-κB in age-stimulated cultured endothelial cells.  Submitted.
    PubMedGoogle Scholar
  • 29 Takahashi K, Ghatei M A, Lam H C, O`Halloran D J, Bloom S R. Elevated plasma endothelin in patients with diabetes mellitus.  Diabetologia . 1990;  33 306-310
    CrossrefPubMedGoogle Scholar
  • 30 Hopfner R L, Gopalakrishnan V. Endothelin: Emerging role in diabetic vascular complications.  Diabetologia . 1999;  42 1383-1394
    CrossrefPubMedGoogle Scholar
  • 31 Khan M A, Dashwood M R, Mumtaz F H. Upregulation of endothelin at receptor sites in the rabbit diabetic kidney: Potential relevance to the early pathogenesis of diabetic nephropathy.  Nephron . 1999;  83 261-267
    CrossrefPubMedGoogle Scholar
  • 32 Sarman B, Toth M, Somogyi A. Role of endothelin-1 in diabetes mellitus.  Diabetes Metab Rev . 1998;  14 171-175
    CrossrefPubMedGoogle Scholar
  • 33 Winkles J A, Alberts G F, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries.  Biophys Res Commun . 1993;  191 1081-1088
    PubMedGoogle Scholar
  • 34 Zeiher A M, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina.  Circulation . 1995;  91 941-947
    PubMedGoogle Scholar
  • 35 Zeiher A M, Ihling C, Pistorius K, Schachinger V, Schaefer H E. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes.  Lancet . 1994;  344 1405-1406
    CrossrefPubMedGoogle Scholar
  • 36 Bruzzi I, Benigni A. Endothelin is a key modulator of progressive renal injury: Experimental data and novel therapeutic strategies.  Clin Exp Pharmacol Physiol . 1996;  23 349-353
    PubMedGoogle Scholar
  • 37 DeMattia G, CassoneFaldetta M, Bellini C. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy.  Am J Hypertens . 1998;  11(Part 1) 983-988
    CrossrefPubMedGoogle Scholar
  • 38 Kohan D E. Endothelins in the normal and diseased kidney.  Am J Kidney Dis . 1997;  29 2-26
    PubMedGoogle Scholar
  • 39 Benigni A, Colosio V, Brena C. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes.  Diabetes . 1998;  47 450-456
    PubMedGoogle Scholar
  • 40 Furchgott R F, Zawadzki J V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.  Nature . 1980;  288 373-376
    CrossrefPubMedGoogle Scholar
  • 41 Palmer R M, Ferrige A G, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.  Nature . 1987;  327 524-526
    CrossrefPubMedGoogle Scholar
  • 42 Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.  J Clin Invest . 1991;  87 432-438
    CrossrefPubMedGoogle Scholar
  • 43 Hunt J V, Smith C CT, Wolff S P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modifications.  Diabetes . 1990;  39 1420-1424
    CrossrefPubMedGoogle Scholar
  • 44 Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biological and clinical implications for diabetes and aging.  Lab Invest . 1994;  70 138-151
    PubMedGoogle Scholar
  • 45 Basta G, De Caterina R. Products of advanced glycosylation and the pathogenesis of accelerated atherosclerosis in diabetes.  G Ital Cardiol . 1996;  26 699-719
    PubMedGoogle Scholar
  • 46 Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications.  Diabetes Care . 1996;  19 257-267
    CrossrefPubMedGoogle Scholar
  • 47 Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension and cardiovascular disease: Which role for oxidative stress?.  Metabolism . 1995;  44 363-368
    CrossrefPubMedGoogle Scholar
  • 48 McCarty M F. Oxidants downstream from superoxide inhibit nitric oxide production by vascular endothelium: A key role for selenium-dependent enzymes in vascular health.  Med Hypothesis . 1999;  53 315-325
    CrossrefPubMedGoogle Scholar
  • 49 Malek A M, Alper S L, Izumo S. Hemodynamic shear stress and its role in atherosclerosis.  JAMA . 1999;  282 2035-2042
    CrossrefPubMedGoogle Scholar
  • 50 Celermajer D S, Sorensen K E, Gooch V M. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.  Lancet . 1992;  340 1111-1115
    CrossrefPubMedGoogle Scholar
  • 51 Joannides R, Haefeli W, Linder L. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo.  Circulation . 1995;  91 1314-1319
    CrossrefPubMedGoogle Scholar
  • 52 Sorensen K E, Celermajer D S, Spiegelthaler D J. Non-invasive measurement of human endothelium dependent arterial responses: Accuracy and reproducibility.  Br Heart J . 1995;  74 247-253
    PubMedGoogle Scholar
  • 53 Balletshofer B M, Rittig K, Enderle M D. Endothelial dysfunction is detectable in young normotensive first degree relatives of subjects with type 2 diabetes in association to insulin resistance.  Circulation . 2000;  101 1780-1784
    PubMedGoogle Scholar
  • 54 Enderle M D, Benda N, Schmuelling R M. Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects.  Diabetes Care . 1998;  21 271-277
    CrossrefPubMedGoogle Scholar
  • 55 King G L, Brownlee M. The cellular and molecular mechanisms of diabetic complications.  Endocrinol Metab . 1996;  25 255-270
    CrossrefPubMedGoogle Scholar
  • 56 Akbari C M, Saouaf R, Barnhill D F. Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia.  J Vasc Surg . 1998;  28 687-694
    PubMedGoogle Scholar
  • 57 Kawano H, Motoyama T, Hirashima O. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.  J Am Coll Cardiol . 1999;  34 146-154
    CrossrefPubMedGoogle Scholar
  • 58 Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system.  Haemostasis . 1993;  23(Suppl I) 118-126
    PubMedGoogle Scholar
  • 59 Galle J, Heermeier K. Angiotensin II and oxidized LDL: An unholy alliance creating oxidative stress.  Nephrol Dial Transplant . 1999;  14 2585-2589
    PubMedGoogle Scholar
  • 60 Pueyo M, Michel J B. Effect of angiotensin II on vascular remodeling.  Nephrologie . 1998;  19 443-449
    PubMedGoogle Scholar
  • 61 Touyz R M, Schiffrin E L. Angiotensin II stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells.  Hypertension . 1999;  34(Part 2 Suppl S) 976-982
    PubMedGoogle Scholar
  • 62 Remme W J. Effect of ACE inhibition on neurohormones.  Eur Heart J . 1998;  19(Suppl J) J16-J23
    CrossrefPubMedGoogle Scholar
  • 63 Mullen M J, Clarkson P, Donald A E. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: A randomized, double-blind study.  J Am Coll Cardiol . 1998;  31 1330-1335
    CrossrefPubMedGoogle Scholar
  • 64 Mäkimattila S, Virkamäki A, Groop P H. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus.  Circulation . 1996;  94 1276-1282
    PubMedGoogle Scholar
  • 65 Makita Z, Yanagisawa K, Kuwajima S. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis.  Nephrol Dial Transplant . 1996;  11(Suppl 5) 31-33
    PubMedGoogle Scholar
  • 66 Mougenot N, Lesnik P, Ramirez-Gil J F. Effect of the oxidation state of LDL on the modulation of arterial vasomotor response in vitro.  Atherosclerosis . 1997;  133 183-192
    CrossrefPubMedGoogle Scholar
  • 67 Posch K, Simecek S, Wascher T C. Glycated low-density lipoprotein attenuates shear stress-induced nitric oxide synthesis by inhibition of shear stress-activated L-arginine uptake in endothelial cells.  Diabetes . 1999;  48 1331-1337
    PubMedGoogle Scholar
  • 68 Koenig W. Atherosclerosis involves more than just lipids: Focus on inflammation.  Eur Heart J Suppl . 1999;  1 T19-T26
    PubMedGoogle Scholar
  • 69 Weissberg P L. Atherosclerosis involves more than just lipids: Plaque dynamics.  Eur Heart J Suppl . 1999;  1 T13-T18
    PubMedGoogle Scholar
  • 70 Sheu W H, Juang B L, Chen Y T, Lee W J. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia.  Diabetes Care . 1999;  22 1224-1225
    PubMedGoogle Scholar
  • 71 Cosentino F, Luscher T F. Endothelial dysfunction in diabetes mellitus.  J Cardiovasc Pharmacol . 1998;  32(Suppl 3) S54-S61
    PubMedGoogle Scholar
  • 72 Pfister M, Seiler C, Fleisch M. Nitrate induced coronary vasodilatation: Differential effects of sublingual application by capsule or spray.  Heart . 1998;  80 365-369
    PubMedGoogle Scholar
  • 73 Cameron N E, Cotter M A. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.  Diabetes Res Clin Pract . 1999;  45 137-146
    CrossrefPubMedGoogle Scholar
  • 74 Nakayama M, Izumi G, Nemoto Y. Suppression of N-epsilon-(carboxymethyl)lysine generation by the antioxidant N-acetylcysteine.  Peritoneal Dial Int . 1999;  19 207-210
    PubMedGoogle Scholar
  • 75 Munzel T, Heitzer T, Harrison D G. The physiology and pathophysiology of the nitric oxide/superoxide system.  Herz . 1997;  22 157-172
    PubMedGoogle Scholar
  • 76 Beverelli F, Bea M L, Puybasset L, Giudicelli J F, Berdeaux A. Chronic inhibition of NO synthase enhances the production of prostacyclin in coronary arteries through upregulation of the cyclooxygenase type 1 isoform.  Fundam Clin Pharmacol . 1997;  11 252-259
    PubMedGoogle Scholar
  • 77 Kawagishi T, Matsuyoshi M, Emoto M. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes.  Arterioscler Thromb Vasc Biol . 1999;  19 2509-2516
    PubMedGoogle Scholar
  • 78 Wautier J L, Zoukourian C, Chappey O. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rat.  J Clin Invest . 1996;  97 238-243
    CrossrefPubMedGoogle Scholar
  • 79 Osicka T M, Yu Y X, Panagiotopoulos S. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C.  Diabetes . 2000;  49 87-93
    PubMedGoogle Scholar
  • 80 Soulis T, Cooper M E, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment.  Kidney Int . 1996;  50 627-634
    PubMedGoogle Scholar
  • 81 He C J, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration.  Diabetes . 1999;  48 1308-1315
    PubMedGoogle Scholar
  • 82 Luscher T F, Noll G. Endothelium dysfunction in the coronary circulation.  J Cardiovasc Pharmacol . 1994;  24(Suppl 3) S16-S26
    PubMedGoogle Scholar
  • 83 Han R O, Ettenson D S, Koo E WY. Heparin/heparan sulfate chelation inhibits control of vascular repair by tissue-engineered endothelial cells.  Am J Physiology . 1997;  42 H2586-H2595
    PubMedGoogle Scholar
  • 84 Elliot S J, Striker L J, Stetler-Stevenson W G, Jacot T A, Striker G E. Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells.  J Am Soc Nephrol . 1999;  10 62-68
    PubMedGoogle Scholar
  • 85 Verrotti A, Catino M, Di-Ricco L, Casani A, Chiarelli F. Prevention of microvascular complications in diabetic children and adolescents.  Acta Paediatr . 1999;  88(Suppl 427) 35-38
    PubMedGoogle Scholar
  • 86 Mogensen C E. Preventing end-stage renal disease.  Diabetic Med . 1998;  15(Suppl 4) S51-S56
    CrossrefPubMedGoogle Scholar
  • 87 Barnes P J, Karin M. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases.  N Engl J Med . 1997;  336 1066-1071
    CrossrefPubMedGoogle Scholar
  • 88 Kislinger T, Fu C F, Huber B. N-epsilon-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.  J Biol Chem . 1999;  274 31740-31749
    CrossrefPubMedGoogle Scholar
  • 89 Borcea V, Morcos M, Isermann B. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.  Vasa . 1999;  28 172-180
    CrossrefPubMedGoogle Scholar
  • 90 Kessler L, Wiesel M L, Attali P. Von Willebrand factor in diabetic angiopathy.  Diabetes Metab . 1998;  24 327-336
    Google Scholar
  • 91 Valensi P, Pariès J, Zkhiri F. Effects of gamma linolenic acid supplementation on rheological properties of erythrocytes in type 2 diabetic patients with peripheral polyneuropathy.  J Mal Vasc . 1996;  21 185-187
    PubMedGoogle Scholar
  • 92 Bursell S E, Clermont A, Aiello L P. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes.  Diabetes Care . 1999;  22 1245-1251
    PubMedGoogle Scholar
  • 93 Seljeflot I, Arnesen H, Brude I R. Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers.  Eur J Clin Invest . 1998;  28 629-635
    CrossrefPubMedGoogle Scholar
  • 94 Jain S K. Should high-dose vitamin E supplementation be recommended to diabetic patients?.  Diabetes Care . 1999;  22 1242-1244
    PubMedGoogle Scholar
  • 95 Celermajer D S, Adams M R, Clarkson P. Passive smoking and impaired endothelium-dependent arterial dilation in healthy young adults.  N Engl J Med . 1996;  334 150-154
    CrossrefPubMedGoogle Scholar
  • 96 Zhan J, Ying X, Lu Q. A single high dose of vitamin C counteracts the acute negative effect on microcirculation induced by smoking a cigarette.  Mikrovasc Res . 1999;  58 305-311
    PubMedGoogle Scholar
  • 97 Poredos P, Orehek M, Tratnik E. Smoking is associated with dose-related increase of intima-media thickness and endothelial dysfunction.  Angiology . 1999;  50 201-208
    PubMedGoogle Scholar
  • 98 Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.  Mol Med . 1999;  5 393-405
    PubMedGoogle Scholar
  • 99 Schleicher E D, Wagner E, Nerlich A G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging.  J Clin Invest . 1997;  99 457-468
    PubMedGoogle Scholar
      >